Temporal risk patterns of severe hypovolemia associated with sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes mellitus: A self‐controlled case series study
SGLT2i use in patients with type 2 diabetes mellitus was associated with a higher risk of severe hypovolemia, particularly within the first 30 days of treatment initiation, with the highest risk observed during 22 to 28 days.
Authors
- Koji Kawakami (ORCID: https://orcid.org/0000-0002-7477-4071)
- Atsushi Takayama (ORCID: https://orcid.org/0000-0003-0479-3733)
- Kasumi Yokogawa
- Mitsuhiro Shikamura (ORCID: https://orcid.org/0000-0002-8980-5811)
Institutions
- Kyoto University (JP)
- Takeda (Japan) (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1111/dom.16259
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00